Read the story about SideROS in CNRS – Centre national de la recherche scientifique Le Journal, one our top hashtag#RISE hashtag#startup which develops new anti-cancer strategies focused on iron contained in the stem cells that usually resists to actual treaments.
Our virtual pitch start-up for BIO-Europe Spring https://lnkd.in/eRdjEqv hashtag#SideROS hashtag#BioEuropeSpring
The start-up SideROS announces €500k seed funding, acquired from business angels, to tackle relapse and metastasis in cancer. Founded in 2019, this French biotech company is the brainchild of chemist Raphaël Rodriguez, CNRS Research Director at Institut Curie.
SideROS was selected for the 2020 EIT Health Headstart programme providing emerging companies with mentorship and funding opportunities for their innovative products and services aiming to improve the lives of European patients and citizens.
The event International Cancer Cluster 2020 highlighted 20 emerging oncology companies who presented their technologies and partnering opportunities in this newly adapted forum, among which company SideROS presented its company and project.
Raphael Rodriguez, Founder of SideROS, was co-author of the recent Nature Chemistry article describing how CD44 regulates epigenetic plasticity by mediating iron endocytosis.
SideROS was among 11 start-ups invited at the Oncology Upward Investment by Matwin to pitch their cancer treatment research project in front of 15 of the largest European investors.
SideROS is finalist for the Start-up Session of IFOD – International & French Oncology Days. SideROS is invited to pitch their cancer treatment research project during IFO Days.